Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$6.32 USD

6.32
697,602

+0.46 (7.85%)

Updated May 22, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (144 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PerkinElmer (PKI) Q4 Earnings Beat, Diagnostics Grows Y/Y

by Zacks Equity Research

PerkinElmer's (PKI) fourth-quarter 2018 results gain from solid segmental contributions.

McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View

by Zacks Equity Research

McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.

Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet

by Zacks Equity Research

Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.

Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top

by Zacks Equity Research

Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.

Edwards Lifesciences (EW) Q4 Earnings In Line, Revenues Top

by Zacks Equity Research

Edwards Lifesciences (EW) Q4 results benefit from growth in all the businesses.

ABIOMED (ABMD) Q3 Earnings Beat, Impella Maintains Momentum

by Zacks Equity Research

ABIOMED's (ABMD) flagship Impella sees a solid Q3; fiscal 2019 outlook raised.

Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.

Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid

by Zacks Equity Research

Surmodics' (SRDX) fiscal Q1 sees solid contributions from all segments.

AmerisourceBergen (ABC) Beats on Q1 Earnings, Trims EPS View

by Zacks Equity Research

AmerisourceBergen (ABC) registers solid growth at the Pharmaceutical Distribution segment and the World Courier business in first-quarter fiscal 2019.

Baxter's (BAX) Earnings, Revenues Beat Estimates in Q4

by Zacks Equity Research

Baxter (BAX) gains from the Renal Care and Advanced Surgery units in fourth-quarter 2018; Clinical Nutrition revenues soft.

Thermo Fisher (TMO) Beats on Earnings and Revenues in Q4

by Zacks Equity Research

Thermo Fisher (TMO) gains on growth in all business segments in Q4.

Align Technology (ALGN) Beats on Earnings and Revenues in Q4

by Zacks Equity Research

Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q4.

Varian Strong on Global Expansion and Proton Therapy Arm

by Zacks Equity Research

Varian's (VAR) strong presence in China instills optimism in the stock.

Stryker (SYK) Q4 Earnings Beat, International Revenues Surge

by Zacks Equity Research

Stryker (SYK) gains from solid segmental contributions in Q4.

Hill-Rom's (HRC) Earnings and Revenues Top Estimates in Q1

by Zacks Equity Research

Hill-Rom (HRC) benefits from a solid year-over-year revenue increase on domestic growth in Q1, driven by strong segmental performance.

Intuitive Surgical (ISRG) Earnings Miss, Revenues Beat in Q4

by Zacks Equity Research

Solid show by flagship da Vinci system drives Intuitive Surgical's (ISRG) Q4 results.

Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up

by Zacks Equity Research

Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.

CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

CONMED's (CNMD) Q4 results get a boost from solid segmental performances.

Here's Why Investors Should Hold AngioDynamics (ANGO) Now

by Zacks Equity Research

AngioDynamics' (ANGO) flagship NanoKnife System is currently witnessing robust demand.

AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife

by Zacks Equity Research

AngioDynamics (ANGO) sees a solid fiscal second quarter; gains from strong segmental contributions.

AngioDynamics (ANGO) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 4.76% and 2.93%, respectively, for the quarter ended November 2018. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Investors Should Hold AngioDynamics Stock Now

by Zacks Equity Research

AngioDynamics' (ANGO) gains from solid prospects in the NanoKnife platform. However, sluggishness in the Venous Insufficiency business is a headwind.

AngioDynamics (ANGO) Down 6.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AngioDynamics (ANGO) Q1 Earnings Miss, '19 Sales View Up

by Zacks Equity Research

AngioDynamics (ANGO) sees soft segmental performances in Q1; international sales surge.